Head and Neck Verrucous Carcinoma: A European Multicenter Retrospective Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42557778.
- Also identified by DOI 10.1002/hed.70423.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We characterized oncological outcomes of head and neck verrucous carcinomas (HNVC) and explored treatment-associated outcomes. Medical records of 106 HNVC patients (1994-2024) were reviewed, analyzing clinical history, tumor characteristics, treatment modality, and outcomes. Among 106 patients, 101 underwent surgery. Five-year overall survival and recurrence-free survival were 82.2% and 85.3%, respectively. Cox regression identified age ≥ 65 years as significantly increasing recurrence risk (HR = 5.989; 95% CI 2.02-17.77), while tobacco consumption decreased risk (HR = 0.309; 95% CI 0.12-0.81). Clinical T stage influenced recurrence: cT2 (HR = 0.22), cT3 (HR = 1.366), cT4 (HR = 1.525). Compared with local resection, partial organ resection (HR = 0.841) and total organ resection (HR = 0.501) showed lower recurrence rates. HNVC demonstrates excellent five-year survival. Surgery remains the primary treatment, with wider resections significantly reducing recurrence risk, emphasizing the importance of achieving clear margins for durable local control.